A simple fiber supplement could reshape the gut microbiome, stabilize blood sugar spikes, and even prevent preterm births in high-risk pregnancies, offering a promising new path for precision prenatal care.
Study: Dietary fiber supplementation mitigates gestational diabetes risk and preterm birth via gut microbiota modulation: a randomized controlled trial. Image credit: dilyaz/Shutterstock.com
A new study in Frontiers in Endocrinology evaluated the efficacy of soluble dietary fiber supplementation in altering gestational glucose metabolism and pregnancy outcomes by modulating the gut microbiome.
Gestational Diabetes and Fiber-Mediated Microbiome Modulation During Pregnancy
Gestational diabetes mellitus (GDM) is a type of high blood sugar (hyperglycemia) that develops during pregnancy, typically in the second or third trimester, and is caused by placental hormones that impair insulin action. It affects 7–10 % of pregnancies globally, with incidence rising in parallel with economic development and lifestyle shifts.
Multiple studies have highlighted that GDM confers significant maternal and neonatal risks, including pregnancy-induced hypertension, preterm delivery, macrosomia, and elevated long-term susceptibility to type 2 diabetes mellitus (T2DM). Therefore, it is crucial to develop targeted preventive strategies, particularly in high-risk populations defined by advanced maternal age, obesity, or familial history of diabetes.
The gut microbiota has emerged as a key regulator of host glucose homeostasis, with dysbiosis increasingly linked to the pathophysiology of GDM. Affected individuals exhibit characteristic shifts in microbial composition, particularly elevated abundances of Corynebacteriales and Bacteroidetes.
Dietary fiber, comprising indigestible plant polysaccharides, has demonstrated protective effects against metabolic dysfunction. High fiber intake during pregnancy has been associated with reduced gestational weight gain and fat accrual, as well as lower postpartum weight retention relative to low-fiber controls.
Epidemiological data further indicate a significant inverse relationship between dietary fiber intake and T2DM risk. These benefits are mechanistically attributed to microbial fermentation of fiber into short-chain fatty acids (SCFAs), which reduces insulin resistance and systemic inflammation. Moreover, selective enrichment of SCFA-producing taxa, such as Prevotella and Bifidobacterium, also contributes to beneficial effects. Despite these established benefits, approximately 70 % of pregnant women consume insufficient dietary fiber.
Assessing the Impact of Dietary Fiber on Gut Microbiota and Gestational Glucose Metabolism
This single-center randomized controlled trial (RCT) examined the effects of dietary fiber on GDM risk, glycemic control, and the gut microbiota. Eligible participants were between 18 and 50 years of age, with a singleton pregnancy, and had at least two GDM risk factors, including age ≥35, pre-pregnancy BMI ≥25 kg/m2, family history of diabetes, history of GDM or polycystic ovary syndrome (PCOS), or prior macrosomia delivery, with no antibiotic or probiotic use during pregnancy.
Women with pre-existing conditions such as hyperthyroidism, liver or pancreatic disease, cardiovascular disease, pre-pregnancy diabetes, or relevant medication use were excluded. Eligible women were stratified by age, GDM history, and BMI. Subsequently, they were randomized to a control group receiving routine prenatal care or a fiber group receiving two daily sachets of soluble dietary fiber powder dissolved in warm water from 20 to 24+6 weeks of gestation.
Adherence was monitored through returned sachets and daily adverse-effect logs. Both groups received standardized nutrition education in accordance with the Chinese Dietary Guidelines for Pregnant Women. All participants underwent a 75-g oral glucose tolerance test (OGTT) at 25–28 weeks. GDM was diagnosed if any threshold was met: fasting plasma glucose (FPG) ≥5.1 mmol/L, 1-hour plasma glucose (PG) ≥10.0 mmol/L, or 2-hour PG≥8.5 mmol/L.
Fiber Intervention Reduces Postprandial Glucose, Gestational Weight Gain, and Preterm Birth Risk
A total of 98 pregnant women (control: 50; fiber group: 48) completed the study, who were well-matched at baseline with no significant differences in age, BMI, pregnancy history, or metabolic parameters, ensuring a reliable comparison between groups.
Dietary fiber supplementation proved beneficial for postprandial glucose regulation. Women in the fiber group exhibited notably lower 1-hour post-glucose levels and reduced area under the curve (AUC and iAUC) values, indicating a more controlled glycemic response. However, fasting glucose, HbA1c, and insulin resistance (HOMA-IR) were not significantly different between groups, reinforcing that benefits were primarily limited to postprandial glycemic excursions.
While the overall GDM diagnosis rate did not differ significantly between groups (20.8 % in the fiber group and 26.0 % in the control group), the fiber group consistently demonstrated better blood sugar control during the OGTT.
Although both groups started with similar weights, the fiber group gained significantly less weight and had a smaller increase in BMI during the 5-week intervention period than the control group. This suggests that dietary fiber helped moderate gestational weight gain during mid-pregnancy, although this effect did not necessarily translate to lower total pregnancy weight gain due to longer gestational duration in the fiber group.
No women in the fiber group experienced preterm birth, compared to a 12 % preterm birth rate in the control group. The fiber group also had a meaningfully higher average gestational age at delivery, 39.04 weeks, compared to 38.33 weeks, suggesting a potential protective effect of fiber on pregnancy duration.
Fiber supplementation led to meaningful shifts in gut microbiota composition. At the phylum level, Bacteroidetes became the most prevalent in the fiber group post-intervention, and Actinobacteriota abundance increased significantly. At the genus level, Bifidobacterium increased substantially while Phascolarctobacterium decreased in the fiber group.
These changes reflect a microbiome profile potentially more favorable for metabolic health, based on associations observed in prior studies rather than direct causal evidence in this trial. Interestingly, alpha-diversity was reduced in the fiber group, which the authors interpret as a possible stabilization of microbial composition, although reduced diversity is not universally beneficial, and its clinical significance remains uncertain.
In the control group, nine bacterial species were linked to glucose metabolism and four to weight, while the fiber group showed fewer such associations, suggesting fiber may have weakened or altered typical links between specific microbes and glucose or weight measures rather than definitively “normalizing” them, and reduced previously observed correlations between certain taxa (e.g., Bifidobacterium-related groups) and fasting glucose.
Functional analysis revealed that the control group’s microbiota was enriched in 22 inflammation-related metabolic pathways, whereas the fiber group showed enrichment in only one, based on predictive functional profiling rather than direct metabolite measurements, indicating fewer predicted disruptions in metabolic and inflammatory pathways.
A combined clinical-microbiome model achieved the strongest GDM predictive performance, outperforming clinical-only and microbiome-only models. However, this model was developed and internally validated in a small cohort and requires external validation before clinical use. The intervention was well tolerated overall, with only mild side effects, such as bloating, dizziness, diarrhea, and abdominal pain, reported in 14.8 % of participants in the fiber group and just 2 withdrawals. Adherence was high, with 83.3 % of completers consuming 95 % or more of the prescribed fiber powder and an average intake rate of 96.6 %.
Conclusions
Dietary fiber supplementation in high-risk pregnancies shows promise for supporting postprandial glucose homeostasis, limiting excess weight gain, and reducing preterm birth risk. These benefits appear to be mediated, at least in part, through the modulation of key gut microbiome, such as Bifidobacterium.
Combining microbiome signatures with clinical metrics further strengthens early GDM risk prediction. However, given the small, single-center design, limited sample size, and reliance on predictive microbiome analyses without direct metabolite measurement, these findings should be considered preliminary. In the future, these findings must be validated using larger, multicenter cohorts and advance precision nutrition in prenatal care.
